Intercept Pharmaceuticals, Inc. – NASDAQ:ICPT

Add to watchlist

Market closed

Open in 2 days

+2.15%

month

+82.87%

quarter

+24.02%

year

Market Cap	794.69M
Enterprise value	945.40M

P/E	-3.03
EV/Sales	2.99
EV/EBITDA	3.90
Price/Sales	2.10
Price/Book	7.12
PEG ratio	N/A
EPS	-1.40

Revenue	317.68M
EBITDA	-41.67M
Income	-58.61M
Revenue Q/Q	14.43%
Revenue Y/Y	-3.82%

Profit margin	70.39%
Oper. margin	-16.43%
Gross margin	99.52%
EBIT margin	-16.43%
EBITDA margin	-13.12%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Profit margin
Dec 2022	77.21M	-20.38M	-26.4%
Mar 2023	67.95M	-29.57M	-43.52%
Jun 2023	83.71M	-5.86M	-7%
Sep 2023	88.78M	-2.79M	-3.14%

Intercept Pharmaceuticals Financials Estimate

Q Y

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Analyst Estimates
2025	361.49M	85.14M	23.55%

Analysts Price target
Financials & Ratios estimates

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Earnings per share (EPS)
2023-11-07	-0.27	-0.07

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Debt to assets
Dec 2022	553711000	460.63M	83.19%
Mar 2023	504085000	436.9M	86.67%
Jun 2023	484635000	417.08M	86.06%
Sep 2023	393162000	321.31M	81.73%

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Cash Flow
Dec 2022	-4.80M	-54.93M	-5.67M
Mar 2023	-51.59M	59.32M	-254K
Jun 2023	-23.30M	96.94M	-43K
Sep 2023	16.68M	59.77M	-109.99M

Intercept Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Intercept Pharmaceuticals
Employees

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Employee count
Aug 2023	341
Sep 2023	341
Oct 2023	341
Nov 2023	341
Dec 2023	341
Jan 2024	341
Feb 2024	341
Mar 2024	341
Apr 2024	341
May 2024	341
Jun 2024	341
Jul 2024	341

Intercept Pharmaceuticals
Hedge Funds Holdings Q1 2022

78.99% -1.35%

of ICPT is owned by hedge funds

142 -2

hedge funds hold ICPT stock

25.19M -304.28K

shares is hold by hedge funds

ICPT hedge funds holdings changes

Intercept Pharmaceuticals
Insider Trading

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Insider trades (number of shares)
Period	Buy	Sel
Apr 2020	0	239
May 2020	0	1786734
Aug 2020	0	8588392
Dec 2020	0	1763
Jan 2021	0	2193
Mar 2021	327000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	12 Mar 2021	AKKARAJU SRINIVAS director director	Common Stock	147,000	N/A	N/A
Purchase	10 Mar 2021	AKKARAJU SRINIVAS director director	Common Stock	90,000	$21.19	$1,907,100
Purchase	10 Mar 2021	AKKARAJU SRINIVAS director director	Common Stock	90,000	N/A	N/A
Sale	5 Jan 2021	KAPADIA SANDIP officer: CFO and Treasurer officer: CFO and Treasurer	Common Stock	2,193	N/A	N/A
Sale	15 Dec 2020	KAPADIA SANDIP officer: CFO and Treasurer officer: CFO and Treasurer	Common Stock	1,763	N/A	N/A
Sale	18 Aug 2020	CAMPAGNA JASON officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	1,192	N/A	N/A
Sale	17 Aug 2020	GENEXTRA S.P.A. 10 percent owner 10 percent owner	Common stock, par value $0.001 per share	1,362,400	$48.45	$66,005,555
Sale	17 Aug 2020	FUNDARO PAOLO director, 10 percent owner director, 10 percent owner	Common stock, par value $0.001 per share	1,362,400	$48.45	$66,005,555
Sale	17 Aug 2020	MICHELI FRANCESCO 10 percent owner 10 percent owner	Common stock, par value $0.001 per share	1,362,400	N/A	N/A
Sale	17 Aug 2020	FUNDARO PAOLO director, 10 percent owner director, 10 percent owner	Common stock, par value $0.001 per share	1,362,400	N/A	N/A

ICPT insider trading transactions

Intercept Pharmaceuticals
Patents

Status	Patent	Filling date	Issue date
Application	Application PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY Filling date: 21 Mar 2022 Issue date: 8 Sep 2022	21 Mar 2022	8 Sep 2022
Application	Application PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY Filling date: 21 Mar 2022 Issue date: 8 Sep 2022	21 Mar 2022	8 Sep 2022
Grant	Grant Utility: Medicine obtained by combining FXR agonist and ARB Filling date: 27 Mar 2017 Issue date: 23 Aug 2022	27 Mar 2017	23 Aug 2022
Grant	Grant Utility: Oral preparation of obeticholic acid Filling date: 30 Mar 2017 Issue date: 16 Aug 2022	30 Mar 2017	16 Aug 2022
Application	Application PHARMACEUTICAL COMPOSITIONS COMPRISING A FXR AGONIST AND A FIBRATE FOR USE IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE Filling date: 29 May 2020 Issue date: 21 Jul 2022	29 May 2020	21 Jul 2022
Application	Application METHODS OF USING OBETICHOLIC ACID Filling date: 23 Jul 2021 Issue date: 16 Jun 2022	23 Jul 2021	16 Jun 2022
Grant	Grant Utility: TGR5 modulators and methods of use thereof Filling date: 2 Sep 2020 Issue date: 31 May 2022	2 Sep 2020	31 May 2022
Grant	Grant Utility: Film-coated tablet having high chemical stability of active ingredient Filling date: 30 Mar 2017 Issue date: 17 May 2022	30 Mar 2017	17 May 2022
Application	Application COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE Filling date: 6 Dec 2021 Issue date: 5 May 2022	6 Dec 2021	5 May 2022
Grant	Grant Utility: 3-desoxy derivative and pharmaceutical compositions thereof Filling date: 18 Sep 2020 Issue date: 3 May 2022	18 Sep 2020	3 May 2022

ICPT patents

Intercept Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q2 2023 2 Aug 2023	Q2 2023 Earnings Call Transcript
Q1 2023 27 Apr 2023	Q1 2023 Earnings Call Transcript
Q4 2022 2 Mar 2023	Q4 2022 Earnings Call Transcript
Q3 2022 1 Nov 2022	Q3 2022 Earnings Call Transcript

ICPT earnings call transcripts

Intercept Pharmaceuticals
Executives

Insider	Age	Since	Compensation
Dr. Mark Pruzanski M.D. (1968) Founder, Advisor & Director	57		$1,300,000
Mr. Jerome B. Durso (1968) Pres, Chief Executive Officer & Director	57		$853,170

Intercept Pharmaceuticals
Latest News

Thursday, 12 December 2024
10:05	US FDA says Intercept's drug can cause liver injury in patients without scarring	reuters.com
Tuesday, 12 November 2024
08:10	US FDA declines full approval for Intercept's liver disease drug	reuters.com
08:00	Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA)	globenewswire.com
Friday, 13 September 2024
16:19	FDA advisers vote against confirmatory data for Intercept's liver disease drug	reuters.com
Wednesday, 11 September 2024
08:48	FDA staff raises efficacy concerns over Intercept's liver disease drug	reuters.com
Monday, 20 May 2024
01:03	Sophos Group (OTCMKTS:SPHHF) & Loomis AB (publ) (OTCMKTS:LOIMF) Financial Review	https://www.defenseworld.net
00:00	Gilead (GILD) Announces Positive Interim Results on PBC Drug	https://www.zacks.com
Thursday, 29 February 2024
08:30	Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC	globenewswire.com
Wednesday, 8 November 2023
09:13	Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.	globenewswire.com
09:12	Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.	businesswire.com
02:08	Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.	businesswire.com
Tuesday, 31 October 2023
11:17	Will Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should Know	Zacks Investment Research
Thursday, 19 October 2023
07:03	Stocks to Sell: 7 Overbought Companies You Ought to Dump Right Now	InvestorPlace
Wednesday, 27 September 2023
06:46	Intercept (ICPT) Stock Jumps 79.2%: Will It Continue to Soar?	Zacks Investment Research
Tuesday, 26 September 2023
14:17	Why Intercept Pharmaceuticals Stock Is Skyrocketing Today	The Motley Fool
14:11	Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?	InvestorPlace
11:42	Intercept Pharmaceuticals stock soars on Alfasigma acquisition deal	Proactive Investors
08:12	Intercept Pharmaceuticals' stock set to soar after Alfasigma buyout deal for an 82% premium	Market Watch
Wednesday, 2 August 2023
11:57	Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y	Zacks Investment Research
11:28	Intercept Pharmaceuticals, Inc. (ICPT) Q2 2023 Earnings Call Transcript	Seeking Alpha
Monday, 26 June 2023
14:16	Intercept (ICPT) to Restructure Operations, Cut Workforce	Zacks Investment Research
Friday, 23 June 2023
13:24	Intercept (ICPT) NDA for NASH Treatment Gets CRL From FDA	Zacks Investment Research
06:49	Intercept to reduce work force by one third as it aims for profitability	Market Watch
Thursday, 22 June 2023
18:00	US FDA declines to approve Intercept's fatty liver disease drug	Reuters
Wednesday, 7 June 2023
15:49	Intercept (ICPT) Announces Positive Data From PBC Study	Zacks Investment Research
Friday, 26 May 2023
08:56	Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)	Benzinga
Monday, 22 May 2023
13:35	Intercept (ICPT) NASH Treatment Fails to Get GIDAC Recommendation	Zacks Investment Research
10:53	Biotech Hits Record Low on FDA Curveball	Schaeffers Research
10:49	Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug	Investors Business Daily
08:00	Intercept shares tumble on concerns over NASH drug prospects	Reuters

Ideas & Opinions

Seeking Alpha 10 Sep 2023

CymaBay: Positive Phase 3 Data And Competitive Advantage Established
Seeking Alpha 13 Jul 2023

Madrigal: With Successful NASH Study, Possible Accelerated Approval Is Next
Seeking Alpha 30 May 2023

Madrigal: Setting The Pace In The NASH Market (Rating Upgrade)
Seeking Alpha 22 May 2023

Intercept Pharmaceuticals: Do Not Expect PBC Sales To Save The Company
Seeking Alpha 11 May 2023

Genfit: Major Data Release Before End Of Q2 Of 2023 Could Get Ball Rolling
Seeking Alpha 30 Mar 2023

A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
Seeking Alpha 24 Jan 2023

Intercept: Huge Potential Upsides With Binary Catalyst Unlocking
Seeking Alpha 26 Dec 2022

Madrigal Pharmaceuticals Setting The Standard
Seeking Alpha 13 Dec 2022

Madrigal: Binary Catalyst Unlocking
Seeking Alpha 13 Dec 2022

Sage Therapeutics Could Be In For A Depressing FDA Review

Frequently Asked Questions (FAQ)

When is Intercept Pharmaceuticals's next earnings date?

Unfortunately, Intercept Pharmaceuticals's (ICPT) next earnings date is currently unknown.
Does Intercept Pharmaceuticals pay dividends?

No, Intercept Pharmaceuticals does not pay dividends.
How much money does Intercept Pharmaceuticals make?

Intercept Pharmaceuticals has a market capitalization of 794.69M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 21.39% to 285.71M US dollars. Intercept Pharmaceuticals earned 115.17M US dollars in net income (profit) last year or -$0.07 on an earnings per share basis.
What is Intercept Pharmaceuticals's stock symbol?

Intercept Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ICPT".
What is Intercept Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Intercept Pharmaceuticals?

Shares of Intercept Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Intercept Pharmaceuticals's key executives?
Intercept Pharmaceuticals's management team includes the following people:
- Dr. Mark Pruzanski M.D. Founder, Advisor & Director(age: 57, pay: $1,300,000)
- Mr. Jerome B. Durso Pres, Chief Executive Officer & Director(age: 57, pay: $853,170)
Is Intercept Pharmaceuticals founder-led company?

Yes, Intercept Pharmaceuticals is a company led by its founder Dr. Mark Pruzanski M.D..
How many employees does Intercept Pharmaceuticals have?

As Jul 2024, Intercept Pharmaceuticals employs 341 workers.
When Intercept Pharmaceuticals went public?

Intercept Pharmaceuticals, Inc. is publicly traded company for more then 12 years since IPO on 11 Oct 2012.
What is Intercept Pharmaceuticals's official website?

The official website for Intercept Pharmaceuticals is interceptpharma.com.
Where are Intercept Pharmaceuticals's headquarters?

Intercept Pharmaceuticals is headquartered at 10 Hudson Yards, New York, NY.
How can i contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals's mailing address is 10 Hudson Yards, New York, NY and company can be reached via phone at +64 6 747 1000.

Intercept Pharmaceuticals, Inc.

interceptpharma.com

Exchange:

NASDAQ

Full time employees:

341

Industry:

Biotechnology

Sector:

Healthcare

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

+64 6 747 1000

10 Hudson Yards
New York, NY 10001

CIK: 0001270073
ISIN: US45845P1084
CUSIP: 45845P108